OB/GYN INFORMATION CENTER

News

Talzenna Approved for Germline BRCA-Mutated, HER2-Negative Breast Cancer

Talzenna Approved for Germline BRCA-Mutated, HER2-Negative Breast Cancer

Talzenna, a poly (ADP-ribose) polymerase (PARP) inhibitor, was evaluated in EMBRACA, an open-label trial that randomized patients with gBRCAm HER2-negative locally advanced or metastatic breast cancer (N=431) to receive talazoparib 1mg or physician's choice of chemotherapy (capecitabine, eribulin, gemcitabine, or vinorelbine).

Liletta Now Approved for Pregnancy Prevention for Up to 5 Years

The expanded approval was supposed by safety and efficacy data from the Phase 3 ACCESS IUS trial (N=1751) in women receiving Liletta. In the trial, Liletta demonstrated >99% efficacy in preventing pregnancy for up to 5 years in a broad patient population.

Weight Loss May Reduce Breast Cancer Risk in Postmenopausal Women

Postmenopausal women with weight loss have a reduced risk for breast cancer.

Opinion

Treating premenopausal women with fibroids and dysmenorrhea

The standard treatment option for premenopausal women who do not wish to get pregnant is hysterectomy.

Teen pregnancy prevention program

The program strives to modify teen attitudes toward sexuality and bring about life-changing behavior.

Reconciling birth plans with reality

Patients who have birth plans should be prepared to make concessions to ensure the safety of their newborn.

Features

A Zebra in the Emergency Department

A Zebra in the Emergency Department

Many cases of vaginal foreign body are unusual and often difficult to detect.

Optimizing Pregnancy Outcomes With Micronutrients

Optimizing Pregnancy Outcomes With Micronutrients

As healthy levels of folic acid, iodine, magnesium, vitamin D, and iron demonstrate improved outcomes in pregnancy, understanding of the function of these essential nutrients on health would benefit family practitioners caring for women of childbearing age.

Sign Up for Free e-newsletters